Expertise in
6
conditions

Dr. Margaret Ragni

Internal Medicine
Hillman Center Pharmacy
5115 Centre Ave, 
Pittsburgh, PA 
Expertise in
6
conditions
Hillman Center Pharmacy
5115 Centre Ave, 
Pittsburgh, PA 

Overview

Margaret Ragni is an Internal Medicine provider in Pittsburgh, Pennsylvania. Dr. Ragni is highly rated in 6 conditions, according to our data. Her top areas of expertise are Blood Clots, Hemophilia A, Von Willebrand Disease (VWD), and Hemophilia B.

Her clinical research consists of co-authoring 161 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Specialist in PA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UPMC
  • EPO
  • PPO

Locations

Hillman Center Pharmacy
5115 Centre Ave, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Drug
Study Drugs: Recombinant Von Willebrand factor, Tranexamic Acid
Study Phase: Phase 3
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drug: Efanesoctocog alfa (BIVV001)
Study Phase: Phase 1
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
Enrollment Status: Completed
Publish Date: February 12, 2025
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Enrollment Status: Terminated
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: Von Willebrand Factor, Tranexamic Acid
Study Phase: Phase 3
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
Enrollment Status: Completed
Publish Date: May 10, 2023
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Biological
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Enrollment Status: Completed
Publish Date: November 10, 2020
Intervention Type: Drug
A Long-Term Follow-Up Study in Subjects With Sever Hemophilia B Who Received Adeno-Associated Viral Vectors Expressing Human Factor IX
A Long-Term Follow-Up Study in Subjects With Sever Hemophilia B Who Received Adeno-Associated Viral Vectors Expressing Human Factor IX
Enrollment Status: Completed
Publish Date: May 15, 2020
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Enrollment Status: Terminated
Publish Date: March 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 12 Less Clinical Trials

161 Total Publications

Gynecologic and obstetric management of girls and women with von Willebrand disease.
Gynecologic and obstetric management of girls and women with von Willebrand disease.
Journal: Haematologica
Published: December 11, 2025
Similar Doctors
Expertise in
78
conditions
Dr. Kaushik P. Patel
Internal Medicine
Expertise in
78
conditions
Dr. Kaushik P. Patel
Internal Medicine

Patel Medical Associates LLC

2409 Brownsville Road, 
Pittsburgh, PA 
 (5.2 miles away)
412-819-3204
Languages Spoken:
English, Gujarati , Hindi
See accepted insurances
Offers Telehealth

Kaushik Patel is a primary care provider, practicing in Internal Medicine in Pittsburgh, Pennsylvania. Dr. Patel is highly rated in 78 conditions, according to our data. His top areas of expertise are Hypertension, Heart Failure, Necrosis, Gastrostomy, and Endoscopy.

Expertise in
82
conditions
Dr. Francis Colangelo
Internal Medicine
Expertise in
82
conditions
Dr. Francis Colangelo
Internal Medicine

Office

3824 Northern Pike Ste 200, 
Monroeville, PA 
 (9.7 miles away)
412-380-2800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francis Colangelo is a primary care provider, practicing in Internal Medicine in Monroeville, Pennsylvania. Dr. Colangelo is highly rated in 82 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), High Cholesterol, Hypertension, and Familial Hypertension.

Expertise in
11
conditions
Dr. Elisa Taffe
Internal Medicine
Expertise in
11
conditions
Dr. Elisa Taffe
Internal Medicine

Allegheny General Hospital

320 E North Ave, 
Pittsburgh, PA 
 (3.2 miles away)
412-359-8820
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elisa Taffe is a primary care provider, practicing in Internal Medicine in Pittsburgh, Pennsylvania. Dr. Taffe is highly rated in 11 conditions, according to our data. Her top areas of expertise are Primary Intestinal Lymphangiectasia, Meige Disease, Lymphangiectasis, and Lymphedema.

Frequently Asked Questions about Dr. Margaret Ragni

How do I make an appointment with Dr. Margaret Ragni?

You can book an appointment with Dr. Margaret Ragni by calling their office at 412-692-4724. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Margaret Ragni a top-rated expert for Blood Clots?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Margaret Ragni is classified as an Elite expert for Blood Clots, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Margaret Ragni specialize in?

While Dr. Margaret Ragni is a Internal Medicine, they have specific expertise in Blood Clots, Hemophilia A, and Von Willebrand Disease (VWD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Margaret Ragni participate in research or clinical trials?

Yes. Dr. Margaret Ragni has published 161 articles and abstracts on conditions like Blood Clots. You can view a list of Dr. Margaret Ragni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Margaret Ragni accept my insurance?

Dr. Margaret Ragni accepts most major insurance plans, including Humana and UPMC. We recommend calling the office directly at 412-692-4724 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ragni's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile